Stay updated with breaking news from Recent Highlights. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace
VITAL study 9-month results expected to be presented at a medical conference in 2021 Prasinezumab Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference PRX004 PRX005 IND expected by 3Q 2021 $80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021 PRX012, a potential treatment for Alzheimer’s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ IND expected by 1Q 2022 Upcoming Investor Conferences Members of the senior management team will present an...
Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b data anticipated in Q4 2021 Phase 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in Q1 2022 Cash runway extends beyond anticipated PUR1800 Ph1b and PUR3100 Ph1/Ph2 data milestones Pulmatrix seeks reaffirmation of 50/50 partnership from Cipla Technologies News provided by Share this article Share this article LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled ...
Prothena Corporation plc: Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update VITAL study 9-month results expected to be presented at a medical conference in 2021 Prasinezumab Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference PRX004 PRX005 IND expected by 3Q 2021 $80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021 PRX012, a potential treatment for Alzheimer's disease, is a high affinity monoclonal antibody targeting a key epitope with...
Sonim Reports First Quarter Results and Accelerating New Product Orders Ships NewRS80 SmartScanners in Q1, Secures $10M Order for Next-Generation Rugged Phones News provided by Share this article (Nasdaq: SONM), a leading U.S. provider of ultra-rugged mobile devices, accessories and solutions designed specifically for task workers physically engaged in their work environments, reported financial results for the first quarter ended March 31, 2021 and provided an update on new product orders. First Quarter 2021 and Recent Highlights Net revenues of $12.2 million, compared with $12.7 millio...